Evolent Health (NYSE:EVH) will be issuing its quarterly earnings data after the market closes on Tuesday, November 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, August 7th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The company had revenue of $144.51 million for the quarter, compared to analysts’ expectations of $141.90 million. Evolent Health had a negative return on equity of 1.82% and a negative net margin of 9.84%.
Shares of NYSE:EVH opened at $22.82 on Friday. The company has a current ratio of 2.59, a quick ratio of 2.59 and a debt-to-equity ratio of 0.12. Evolent Health has a 12-month low of $10.30 and a 12-month high of $29.05.
In other Evolent Health news, CEO Frank J. Williams sold 37,909 shares of the business’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $24.02, for a total value of $910,574.18. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Lydia Stone sold 6,805 shares of the business’s stock in a transaction on Thursday, August 30th. The stock was sold at an average price of $25.00, for a total value of $170,125.00. The disclosure for this sale can be found here. In the last three months, insiders sold 204,607 shares of company stock worth $5,240,751. Insiders own 4.82% of the company’s stock.
EVH has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $37.00 target price on shares of Evolent Health in a research report on Wednesday, September 12th. Jefferies Financial Group reaffirmed a “buy” rating and set a $25.00 target price on shares of Evolent Health in a research report on Tuesday, August 7th. KeyCorp lifted their target price on Evolent Health from $26.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, August 20th. ValuEngine raised Evolent Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 14th. Finally, Citigroup lifted their target price on Evolent Health from $25.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, October 4th. One analyst has rated the stock with a sell rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $30.09.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Recommended Story: Moving Average (MA)
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.